Investor Eye: Sofinnova Speaks On Deal Execution, Managing Expertise And what’s In Store For The Future

Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.